Daniel Sammartino
Hematology · White Plains, NYNPI 1184923898
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by AstraZeneca at 31.6% of the total. 2025 is the largest year on record at $2,007, 2.4 times the $826 reported in 2019.
Across 162 payments — averaging $46.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- E.r. Squibb & Sons, L.L.C.$918
- Novartis$800
- Beigene USA, Inc.$675
- Amgen$478
- Incyte Corporation$252
- plus $2K from 32 others
Across 69 payments — averaging $1605.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$111K
- E.r. Squibb & Sons, L.L.C.$89
What the payments were for
- Consulting fees$2,90539%
- Speaking & faculty fees$2003%
- Food & beverage$4,17056%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $2,363 |
| E.r. Squibb & Sons, L.L.C. | 21 | $918 |
| Novartis | 39 | $800 |
| Beigene USA, Inc. | 1 | $675 |
| Amgen | 21 | $478 |
| Incyte Corporation | 6 | $252 |
| Novocure GmbH | 1 | $200 |
| AVEO Pharmaceuticals, Inc. | 5 | $166 |
| Pfizer | 8 | $165 |
| Johnson & Johnson(2 entities) | 7 | $143 |
| Dova Pharmaceuticals | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Seagen Inc. | 1 | $122 |
| Bristol Myers Squibb | 5 | $99 |
| Sanofi | 3 | $79 |
| Stemline Therapeutics Inc. | 1 | $72 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Karyopharm Therapeutics Inc. | 3 | $60 |
| Exelixis Inc. | 2 | $46 |
| Myriad Genetic Laboratories, Inc. | 2 | $43 |
| Servier Pharmaceuticals LLC | 2 | $39 |
| Sobi, Inc | 1 | $37 |
| Merck | 2 | $36 |
| Foundation Medicine, Inc. | 2 | $35 |
| Bayer | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Coherus Oncology, Inc. | 2 | $27 |
| EMD Serono, Inc. | 1 | $27 |
| Novocure Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Clovis Oncology, Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $15 |
| Legend Biotech USA Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,475 in reported general payments places this provider in the 70th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 24 | $455,603 |
| VonjoPacritinib Citrate | 17 | $417,806 |
| PomalystPomalidomide | 13 | $293,967 |
| BrukinsaZanubrutinib | 16 | $259,497 |
| Lenalidomide | 16 | $222,524 |
| CalquenceAcalabrutinib Maleate | 12 | $173,721 |
| Abiraterone Acetate | 30 | $143,841 |
| EliquisApixaban | 179 | $134,585 |
| XareltoRivaroxaban | 39 | $33,966 |
| CreonLipase/Protease/Amylase | 13 | $28,567 |
| Enoxaparin Sodium | 18 | $5,667 |
| Hydroxyurea | 46 | $1,870 |
| Imatinib Mesylate | 13 | $1,318 |
| Levothyroxine Sodium | 48 | $547 |
| Oxycodone Hcl | 15 | $542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $99 | $455,60324 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $918 | $293,96713 claims |
| Beigene USA, Inc.Brukinsa | $675 | $259,49716 claims |
| AstraZenecaCalquence | $2,363 | $173,72112 claims |
| PfizerEliquis | $165 | $134,585179 claims |
| Johnson & JohnsonXarelto | $143 | $33,96639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 hematology providers in New York.
Other hematology in White Plains
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.